Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Asset Writedowns and Impairment (2018 - 2020)

Catheter Precision (VTAK) reported Asset Writedowns and Impairment of $155000.0 for Q4 2020, up 811.76% year-over-year from $17000.0 in Q1 2020, and up 1450.0% on a QoQ basis from $10000.0 in Q2 2020.

Catheter Precision (VTAK) has 3 years of Asset Writedowns and Impairment data on file, last reported at $155000.0 in Q4 2020.

  • Quarterly Asset Writedowns and Impairment rose 811.76% year-over-year to $155000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $180000.0 (down 36.4% YoY) and the FY2025 annual result came in at $7.0 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment rose to $155000.0 in Q4 2020 per VTAK's latest filing, from $10000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $242000.0 in Q2 2019 and bottomed at $10000.0 in Q2 2020.
  • The 3-year median for Asset Writedowns and Impairment is $24000.0 (2019), against an average of $78714.3.
  • Peak annual rise in Asset Writedowns and Impairment reached 811.76% in 2020, while the deepest fall reached 95.87% in 2020.
  • Tracing VTAK's Asset Writedowns and Impairment over 3 years: stood at $88000.0 in 2018, then plunged by 80.68% to $17000.0 in 2019, then surged by 811.76% to $155000.0 in 2020.
  • Per Business Quant, the three latest VTAK Asset Writedowns and Impairment figures stand at $155000.0 (Q4 2020), $10000.0 (Q2 2020), and $15000.0 (Q1 2020).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Catheter Precision 2.01 Mn 1.20 Mn 390,000.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2020 155,000.00
Dec 31, 2020 155,000.00
Jun 30, 2020 10,000.00
Jun 30, 2020 10,000.00
Mar 31, 2020 15,000.00
Mar 31, 2020 15,000.00
Dec 31, 2019 17,000.00
Dec 31, 2019 17,000.00
Jun 30, 2019 242,000.00
Jun 30, 2019 242,000.00
Mar 31, 2019 24,000.00
Mar 31, 2019 24,000.00
Mar 31, 2018 88,000.00
Mar 31, 2018 88,000.00